Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation

Cinacalcet is indicated for treatment of secondary hyperparathyroidism in patients receiving hemodialysis. Cinacalcet reduces serum calcium concentrations by decreasing parathyroid hormone secretion, but the frequency and degree of calcium reduction following cinacalcet initiation, subsequent physician response, and ultimate calcium recovery in clinical practice are not well described.

[1]  Jiannong Liu,et al.  Evaluating Real-World Use of Cinacalcet and Biochemical Response to Therapy in US Hemodialysis Patients , 2013, American Journal of Nephrology.

[2]  J. Romijn,et al.  Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. , 2013, European journal of endocrinology.

[3]  Huiliang Xie,et al.  Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[4]  G. Chertow,et al.  Self‐reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low‐dose vitamin D sterols , 2012, Hemodialysis international. International Symposium on Home Hemodialysis.

[5]  John Cunningham,et al.  Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[6]  M. Vervloet,et al.  Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  Alison M. MacLeod.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) , 2009 .

[8]  Jiannong Liu,et al.  Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[9]  M. Iwasaki,et al.  Long-Term Cinacalcet HCl Treatment Improved Bone Metabolism in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism , 2008, American Journal of Nephrology.

[10]  B. Bammens,et al.  Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism , 2008, Nephron Clinical Practice.

[11]  David Martin,et al.  The Role of the Calcium-Sensing Receptor in the Pathophysiology of Secondary Hyperparathyroidism , 2008, NDT plus.

[12]  M. Chonchol,et al.  Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease , 2008, NDT plus.

[13]  P. Torres.  Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. , 2006, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[14]  F. Port,et al.  Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. , 2005, Kidney international.

[15]  B. Culleton,et al.  Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. , 2005, Journal of the American Society of Nephrology : JASN.

[16]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[17]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[18]  D. Lacey,et al.  Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl , 2004, Journal of Pharmacology and Experimental Therapeutics.

[19]  S. Rosansky,et al.  The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[20]  D. Churchill,et al.  Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  M. Perazella,et al.  Biochemical aberrations in a dialysis patient following parathyroidectomy. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  A. Brasier,et al.  Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. , 1988, The American journal of medicine.

[23]  F. Locatelli,et al.  The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[24]  National Kidney Foundation K-DOQI: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease , 2007 .

[25]  M. Florescu,et al.  International Journal of Nephrology and Renovascular Disease Dovepress Calcium Supplementation after Parathyroidectomy in Dialysis and Renal Transplant Patients , 2022 .